CAR-T Surprises Lupus Researchers 5 Years On
Why it matters: This breakthrough offers new hope to millions of patients suffering from autoimmune diseases like lupus.
- Georg Schett successfully treated a lupus patient with CAR-T cells, a therapy previously feared to exacerbate autoimmune diseases.
- Fabian Müller, Schett's collaborator, recounted the initial parental reluctance, highlighting the significant scientific paradigm shift this treatment represented.
- The patient remains in remission five years later and now works in the same clinic, serving as a powerful testament to the therapy's long-term efficacy and safety.
Five years ago, physician-scientist Georg Schett pioneered a groundbreaking CAR-T cell therapy for a young lupus patient, despite initial skepticism from the patient's parents and the prevailing fear that T cells could worsen autoimmune conditions. This audacious treatment resulted in a complete and lasting remission, fundamentally challenging prior assumptions about autoimmune disease and sparking a wave of new research and investment in the field.
